Brief: Aprea Therapeutics Announces Submission of IND Application for APR-1051
06/02/2024 14:35
Feb 6 (Reuters) - Aprea Therapeutics Inc APRE.O :
* APREA THERAPEUTICS ANNOUNCES SUBMISSION OF IND APPLICATION
FOR
APR-1051, A NEXT GENERATION WEE1 KINASE INHIBITOR
* APREA THERAPEUTICS INC - PENDING CLEARANCE OF IND BY FDA,
WE
PLAN TO COMMENCE CLINICAL TESTING IN FIRST HALF OF 2024
Source text for Eikon: ID:nGNX72Cs0G
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing